



Q3 2023 CORPORATE UPDATE

TSXV: **VPT** | OTCQB: **VPTDF**

December 2023

FORWARD LOOKING STATEMENTS

Ventripoint Diagnostics Disclaimer

The information in this presentation may include forward-looking statements related to our future growth, trends in our industry, our financial and or operational results, and our financial or operational performance. Such forward-looking statements are predictive in nature, and may be based on current expectations, forecasts or assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from the forward-looking statements themselves. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, or similar expressions, or may employ such future or conditional verbs as “may”, “will”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For these statements, we claim the protection of the safe harbour for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. The risks and uncertainties referred to above include, but are not limited to: variability of operating results among periods; inability to retain or grow our business due to execution problems resulting from significant headcount reductions, plant closures and product transfer associated with major restructuring activities; the effects of price competition and other business and competitive factors generally affecting the EMS industry; the challenges of effectively managing our operations during uncertain economic conditions; our dependence on a limited number of customers; our dependence on industries affected by rapid technological change; the challenge of responding to lower-than-expected customer demand; our ability to successfully manage our international operations; and delays in the delivery and/or general availability of various components used in the manufacturing process. These and other risks and uncertainties and factors are discussed in the Company’s various public filings at www.sedar.com and www.sec.gov, including our Form 20-F and subsequent reports on Form 6-K filed with the Securities and Exchange Commission. Except as required by applicable law, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Review of Financials

Deferred Revenue

\$71,984

Recorded as revenue when the units are fully operational

Cashflow

\$2,303,405

G&A expenses decreased to \$572,592
R&D expenses increased to \$408,586
M&S expenses decreased to \$198,877

Net losses

\$1,174,285

Recorded a net loss of \$1,174,285, compared with a net loss of \$1,404,688 in 2022



A Year of Transformation



STRATEGIES FOR DRIVING GROWTH

- ➔ Broaden leadership in the CHD market and then expand into other market segments
- ➔ Focus on expanding into new user segments
- ➔ Accelerating integration into OEM and becoming standard of care




- Actively participating in industry congresses, conferences, and workshops.
- Hosting webinars and video content

- Medical journal publications and poster presentations
- White papers and case studies
- Evaluations of the product





Ventripoint-Ascend Partnership

- Ventripoint's AI-powered 3D Echo software application has been integrated with ASCEND's diagnostic viewer, InView, and reporting application, Cardiovascular Structured Reporting.
- This cardiovascular workflow product provides an end-to-end solution that rivals other products on the market.
- ASCEND is seamlessly integrated with leading EHRs, and imaging systems. Their existing technology has been installed at 1000+ top ranked healthcare facilities and 600+ health systems with approximately 50,000 users across the United States.



The Future





Ventripoint
Diagnostics Ltd.

THANK YOU!

www.ventripoint.com